
Study Period | 2019 - 2030 |
Base Year For Estimation | 2024 |
Market Size (2025) | USD 3.90 Billion |
Market Size (2030) | USD 7.35 Billion |
CAGR (2025 - 2030) | 13.50 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players![]() *Disclaimer: Major Players sorted in no particular order |
Non-invasive Prenatal Testing Market Analysis
The Non-Invasive Prenatal Testing Market is expected to register a CAGR of 13.5% during the forecast period.
Non-invasive prenatal testing (NIPT) and different test type is gaining prominence for its capability to assess the likelihood of certain congenital disabilities in unborn babies. NIPT, a cutting-edge advancement in prenatal diagnostics, utilizes methods such as next-generation sequencing and other high-throughput analysis tools to examine free placental DNA from maternal blood serum. Due to its advanced technologies and heightened accuracy, global demand and adoption rates of noninvasive prenatal testing are surging, a trend poised to propel market growth in the coming years.
As NIPT plays a crucial role in detecting chromosomal abnormalities, its rising demand is propelling market growth during the forecast period. For instance, as per the article published in January 2024 in Heliyon Journal, NIPT screening has the potential to enhance the detection of fetal sex chromosome abnormalities, copy number variation (CNVs), and other chromosomal issues while also reducing the false positive rate. Moreover, the detection rate of fetal sex chromosome abnormalities and overall chromosomal issues in pregnant women over 35 has seen a significant uptick, suggesting that advanced maternal age could be a risk factor for fetal chromosomal abnormalities. Hence, such studies highlight the benefits of NIPT, which accentuates the demand for the non-invasive prenatal screening market over the forecast period.
Furthermore, governments' increased support to conduct pre-natal testing for pregnant women across various nations is expected to potentially drive market growth rate in the coming years. For example, in April 2023, the Government of the Netherlands mentioned that all pregnant women can access the non-invasive prenatal test (NIPT) without needing to participate in a scientific study. This blood test screens for potential indicators of Down's syndrome, Edwards' syndrome, and Patau's syndrome in unborn children. NIPT is now integrated into standard prenatal screenings.
Similarly, various non-governmental organizations are collaborating with the government to reform the guidelines for prenatal testing, which is likely to promote market growth over the forecast period. For instance, in January 2023, Myriad Genetics, Inc., a frontrunner in genetic testing and precision medicine, voiced its endorsement of the latest guideline update from the American College of Medical Genetics and Genomics (ACMG). This update underscores the clinical significance of non-invasive prenatal screening (NIPS) in detecting various chromosomal abnormalities.
Overall, the increase in research activities showcasing the importance of NIPT, launches of prenatal screening programs, and the rise in strategic activities by the key players are expected to drive the non-invasive prenatal testing market during 2024 to 2029. However, a lack of skilled labor and stringent regulatory and ethical concerns are expected to hinder market growth over the forecast period.
Non-Invasive Prenatal Testing Market Insights and Trends
Down Syndrome Segment Dominates the Non-invasive Prenatal Testing Market
By application, the down syndrome segment is expected to have a significant market share with a CAGR of 13.49% over the forecast period (2024-2029), says this Mordor Intelligence industry report. Market research estimates that the down syndrome segment is expected to have a market size of USD 1.81 billion in 2024 and is likely to reach a market value of USD 3.42 billion by 2029.
Down syndrome arises when an individual possesses an additional chromosome or a fragment of one. This surplus chromosome alters the developmental trajectory of a baby's body and brain, leading to potential mental and physical challenges throughout their life. Non-invasive prenatal testing (NIPT) detects Down syndrome by analyzing cell-free DNA (cfDNA) found in the mother's bloodstream. As non-invasive prenatal testing (NIPT) for Down syndrome becomes a standard component of routine prenatal care, understanding NIPT’s risks, benefits, and limitations is essential.
Key drivers fueling the growth of the Down syndrome segment include a heightened number of Down syndrome cases and an increase in awareness regarding NIPT among pregnant women. As cases of Down syndrome rise, the segment is poised for growth. The National Center on Birth Defects and Developmental Disabilities reported in 2023 that Down syndrome remains the leading chromosomal disorder in the United States. Annually, around 6,000 infants in the United States are diagnosed with Down syndrome, translating to roughly 1 in every 700 births. Thus, owing to the emerging cases of Down syndrome, the need for prenatal testing increases, leading to segment growth over the forecast period.
Moreover, numerous research studies underscore the significance of NIPT in Down syndrome testing, a factor anticipated to propel segment growth during the forecast period. For instance, as per the article published in May 2024 in the PLoS One Journal, the study mentioned that advancements in DNA sequencing technology had paved the way for the adoption of Non-Invasive Prenatal Testing (NIPT) as a screening tool for Down Syndrome (DS) during pregnancy. NIPT identifies and analyzes cell-free DNA (cf-DNA) released from the placenta into the mother's bloodstream. This is achieved through high-throughput techniques, including chromosome-selective sequencing, massively parallel shotgun sequencing, and single-nucleotide polymorphism-based methods. Given the advantages of NIPT in Down syndrome testing, demand is projected to increase. Consequently, end users stand to gain from these advancements, fueling segment growth throughout the forecast period.

Kits and Reagents Segment is Expected to Hold a Major Market Share , by Component
The kits and reagents segment as the component is expected to have a significant non-invasive prenatal testing market share with a CAGR of 14.05% over the forecast period (2024-2029). This industry analysis estimates that the Kits and Reagents segment is expected to have a market size of 1.71 billion in 2024 and is likely to reach a market value of USD 3.18 billion by 2029.
The segment is projected to expand during the forecast period, driven by factors including rising demand for genetic testing, increased maternal age, expanding test capabilities, and increasing awareness of these tests.
The non-invasive prenatal testing market is segmented into components, applications, and end users. By component, the market is segmented into instruments, kits and reagents, and services. By application, the market is segmented into Down syndrome, Edwards syndrome, Patau syndrome, turner syndrome, and other applications. By end user, the market is segmented into hospitals and diagnostic labs. This broader market segmentation aids key stakeholders in pinpointing crucial market analyses.
North America is Expected to Witness Significant Growth in the Global Non-Invasive Prenatal Testing Market
By geography, the North America region is likely to hold a major non-invasive prenatal testing market share with an estimated market size of USD 1.36 billion in 2024, expected to reach USD 2.39 billion by 2029, with a CAGR of 11.97%. North America is expected to have the largest share throughout the period of this market forecast due to the high preterm birth rates, rising burden of chromosomal abnormalities in newborns, and the availability of well-equipped diagnostic centers and testing laboratories in the country.
Additionally, the increasing acceptance and preference of non-invasive prenatal testing (NIPT), and the growing focus on reimbursement for non-invasive prenatal testing in the country are also increasing the demand for NIPT, hence propelling the regional as well as global market growth. Prenatal screening for chromosomal abnormalities, including sex chromosomal aneuploidy, enables doctors and patients to evaluate the risk of chromosomal conditions in fetuses, such as Down syndrome, Edward's syndrome, and Patau syndrome. Consequently, as the prevalence of chromosomal abnormalities in newborns rises, so does the demand for Non-Invasive Prenatal Testing (NIPT), which is poised to drive market growth in the country.
For instance, a report from the Minnesota Department of Health in March 2023 highlighted that while Trisomy 18's occurrence increases with maternal age, it can manifest in parents of any age. In the U.S., Trisomy 18 appears in approximately 1 in every 2000-6000 live births.
In another instance, a June 2023 report from the Centers for Disease Control and Prevention (CDC) noted that Down syndrome rates in United States babies have risen to 1 in every 707 births. Such statistics underscore the significant prevalence of genetic disorders in newborns, suggesting a heightened demand for prenatal testing among expectant mothers and, in turn, fueling market growth during the study period.
In Canada, various programs offer the NIPT at no cost. For example, an April 2023 report from the Government of Quebec highlights the Québec Prenatal Screening Program, which provides free prenatal screenings for trisomy 21, trisomy 18, and trisomy 13 to expectant individuals.
Moreover, as of April 3, 2023, individuals expecting twins became eligible for non-invasive prenatal testing. This testing is being gradually introduced at health and social services institutions across Quebec. Consequently, with the availability of these complimentary tests, their usage in the country is poised to rise, driving market growth during the forecast period.
Consequently, the rising adoption of these services and products in chronic disease management is poised to drive market expansion in the United States, Canada, and Mexico.
Additionally, technological advancements and regulatory approvals and developments for the NIPT are poised to bolster the region's market growth. For example, in May 2023, Health Canada granted regulatory approval to Devyser for its non-invasive fetal RHD testing product. Diagnostic laboratories utilize Devyser’s RHD product to non-invasively determine the RHD status of fetuses using maternal blood samples. Consequently, such product approvals will raise the use of NIPT across North America, fuelling the market growth during the forecast period.
As a result of the heightened risk of chromosomal abnormalities in newborns linked to advanced maternal age, coupled with government-backed recommendations and reimbursements, the establishment of new laboratories, and the approval of new products, the North American non-invasive prenatal testing market is poised for growth during 2024-2029.
By geography, the market is segmented into North America (United States, Canada, Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), and South America (Brazil, Argentina, Rest of South America). Furthermore, emerging countries like East Africa and other Middle Eastern countries demand advanced NIPT technologies to meet the emerging demand, which is expected to propel the market growth over the forecast period.

Non-Invasive Prenatal Testing Industry Overview
The non-invasive prenatal testing industry is very competitive, with most players competing to maximize their market shares. Key players in the non-invasive prenatal testing market research are BGI, Eurofins Scientific, F. Hoffmann-La Roche Ltd, Invitae Corporation, Illumina Inc., Natera Inc., PerkinElmer Inc., Centogene NV, MedGenome Labs Ltd, Myriad Womens Health Inc., Qiagen. among others.
Currently, several major players, including market leaders, command a substantial share and a dominant stance in the market. These pivotal players emphasize technological innovations in their offerings, especially focusing on enhancing the market value of their products. Such concentrated endeavors are set to propel market growth in the foreseeable future.
For instance, in September 2023, TDL transitioned its NIPT testing from Harmony to the Illumina VeriSeq NIPT Solution v2. The Illumina VeriSeq NIPT Solution v2 analyzes the same conditions as Harmony, with added options for fetal sex and sex chromosome aneuploidies. Consequently, strategic product launches by key companies are set to drive market growth and influence market trends during the forecast period.
Non-invasive Prenatal Testing Market Leaders
-
Centogene NV
-
Eurofins Scientific
-
PerkinElmer Inc
-
BGI
-
F. Hoffmann-La Roche Ltd.
- *Disclaimer: Major Players sorted in no particular order

Non-invasive Prenatal Testing Market News
- October 2024: Yourgene Health, part of the Novacyt group of companies and a prominent player in the international molecular diagnostics arena, rolled out the inaugural non-invasive prenatal testing (NIPT) workflow in Colombia. This milestone took place at Genetix, a cutting-edge medical entity renowned for its expertise in human genetic diagnosis. Leveraging Yourgene’s IONA Nx NIPT Workflow, the service promises swift and precise NIPT results for expectant parents in Colombia, thereby mitigating turnaround delays and shipping challenges.
- April 2024: BillionToOne, a molecular diagnostics firm dedicated to making powerful and precise tests universally accessible, achieved a significant milestone: testing over 80,000 patients for Rh incompatibility. This condition arises when a pregnant individual with Rh-negative blood carries a baby with Rh-positive blood. While rare, this incompatibility can result in a severe complication where the pregnant individual's immune system mistakenly targets the baby's red blood cells as foreign.
- May 2024: Natera, Inc., a global frontrunner in cell-free DNA (cfDNA) and genetic testing, unveiled a novel cfDNA-based fetal RhD test. This launch is timely for the healthcare sector, as it aids physicians in patient care amidst widespread shortages of Rho(D) immune globulin therapy (RhIg) across the United States. Natera's test, capable of being conducted as early as nine weeks into gestation, assesses the fetal RhD status using blood samples from pregnant patients. This includes analysis of intricate pseudogene and RhD-CE-D hybrid variants.
- April 2023: Mediclinic launched safe, non-invasive prenatal testing (NIPT) for expectant parents, expanding its DNA-based diagnostic and clinical interpretation services. This launch comes on the heels of Mediclinic's earlier introduction of Ancestry testing services.
Non-invasive Prenatal Testing Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Number of Babies with Chromosomal Disorders Owing to Increasing Number of Late Pregnancies
- 4.2.2 Increasing Demand for Early and Non-Invasive Fetal Diagnosis
- 4.2.3 Favorable Reimbursement Policies
-
4.3 Market Drivers
- 4.3.1 Lack of Skilled Professionals
- 4.3.2 Stringent Regulations and Ethical Concerns
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value in USD Billion)
-
5.1 By Component
- 5.1.1 Instruments
- 5.1.2 Kits and Reagents
- 5.1.3 Services
-
5.2 By Application
- 5.2.1 Down Syndrome (Trisomy 21)
- 5.2.2 Edwards Syndrome (Trisomy 18)
- 5.2.3 Patau Syndrome (Trisomy 13)
- 5.2.4 Turner Syndrome
- 5.2.5 Other Applications
-
5.3 By End User
- 5.3.1 Hospitals
- 5.3.2 Diagnostic Labs
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 BGI
- 6.1.2 Eurofins Scientific
- 6.1.3 F. Hoffmann-La Roche Ltd
- 6.1.4 Invitae Corporation
- 6.1.5 Illumina Inc.
- 6.1.6 Natera Inc.
- 6.1.7 PerkinElmer Inc.
- 6.1.8 Centogene NV
- 6.1.9 MedGenome Labs Ltd
- 6.1.10 Myriad Womens Health Inc.
- 6.1.11 Qiagen
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Non-invasive Prenatal Testing Industry Segmentation
As per the scope of the report, non-invasive prenatal testing (NIPT), which is also called non-invasive prenatal screening (NIPS), is a method for determining the risk that the fetus will be born with certain genetic abnormalities. It is based on analysis of cell free DNA (cfDNA) in maternal blood. This testing analyzes small DNA fragments circulating in a pregnant woman's blood. NIPT analyzes the genetic information contained in this DNA to screen for a number of abnormalities.
The non-invasive prenatal testing market is segmented into components, applications, end users and geography. By component, the market is segmented into instruments, kits and reagents, and services. By application, the market is segmented into Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), turner syndrome, and other applications. By end user, the market is segmented into hospitals and diagnostic labs. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle-East and Africa, and South America. The report offers the value (in USD Billion) for the above segments.
By Component | Instruments | ||
Kits and Reagents | |||
Services | |||
By Application | Down Syndrome (Trisomy 21) | ||
Edwards Syndrome (Trisomy 18) | |||
Patau Syndrome (Trisomy 13) | |||
Turner Syndrome | |||
Other Applications | |||
By End User | Hospitals | ||
Diagnostic Labs | |||
Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Non-invasive Prenatal Testing Market Research FAQs
What are the key players in the non-invasive prenatal testing market?
Key market players are BGI, Eurofins Scientific, F. Hoffmann-La Roche Ltd, Invitae Corporation, Illumina Inc., Natera Inc., Qiagen, Laboratory Corp. of America Holdings, and Quest Diagnostics, among others
What is the market size for Non-Invasive Prenatal Testing?
The global non-invasive prenatal testing market size is estimated at USD 3.90 billion in 2025 and is expected to reach USD 7.35 billion by 2030, growing at a CAGR of 13.50% during the forecast period (2025-2030).
What are the current trends in the non-invasive prenatal testing market?
Current trends underscore the rising adoption and technological evolution of non-invasive prenatal testing (NIPT). Originally focused on detecting trisomies 13, 18, and 21, NIPT is now broadening its scope to encompass microdeletions and autosomal dominant diseases, all while showcasing high sensitivity and minimal false positive rates. This method leverages cell-free fetal DNA extracted from maternal blood. Recent innovations, such as trophoblast retrieval from the cervix (TRIC), promise advantages over conventional techniques.
What are the challenges facing the non-invasive prenatal testing market players?
Key challenges faced by the market are a lack of skilled labor and stringent regulatory and ethical concerns.
What are the emerging technologies in non-invasive prenatal testing?
Emerging technologies in non-invasive prenatal testing (NIPT) are whole genome sequencing, single molecule sequencing, artificial intelligence etc, which focus on enhancing accuracy and expanding the range of detectable conditions.